Search Results for: CTNNB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
H1-2 H1.2 linker histone, cluster member
  • Apoptosis induced DNA fragmentation
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
HIF1A hypoxia inducible factor 1 subunit alpha
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Cellular response to hypoxia
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Expression
  • PTK6 promotes HIF1A stabilization
  • Neddylation
  • STAT3 nuclear events downstream of ALK signaling
  • Regulation of PD-L1(CD274) transcription
  • Carvedilol
  • Hydralazine
  • 2-Methoxyestradiol
  • ENMD-1198
  • PX-478
  • FG-2216
  • Vadadustat
HNF1A HNF1 homeobox A
  • Regulation of gene expression in beta cells
  • D-norleucine
  • Maturity onset diabetes of the young (MODY)
HNF4A hepatocyte nuclear factor 4 alpha
  • Nuclear Receptor transcription pathway
  • Nephron development
  • Lauric acid
  • AVI-4557
  • Myristic acid
  • Maturity onset diabetes of the young (MODY)
IGF2BP1 insulin like growth factor 2 mRNA binding protein 1
  • Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA
  • MAPK6/MAPK4 signaling
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Regulation of NF-kappa B signaling
  • PKR-mediated signaling
  • SLC15A4:TASL-dependent IRF5 activation
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Modulation of host responses by IFN-stimulated genes
  • Mesalazine
  • Acetylsalicylic acid
  • Auranofin
  • Arsenic trioxide
  • MLN0415
  • Acetylcysteine
  • Ertiprotafib
  • Fostamatinib
IQGAP1 IQ motif containing GTPase activating protein 1
  • Nephrin family interactions
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • RHO GTPases activate IQGAPs
  • MAP2K and MAPK activation
  • Neutrophil degranulation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • RHOA GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOQ GTPase cycle
  • RHOU GTPase cycle
  • RHOV GTPase cycle
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Artenimol
JADE1 jade family PHD finger 1
  • HATs acetylate histones
KAT2A lysine acetyltransferase 2A
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HATs acetylate histones
  • Notch-HLH transcription pathway
  • B-WICH complex positively regulates rRNA expression
  • Ub-specific processing proteases
  • RNA Polymerase I Transcription Initiation
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Cardiogenesis
  • Formation of WDR5-containing histone-modifying complexes
  • Formation of paraxial mesoderm
  • Coenzyme A
KAT2B lysine acetyltransferase 2B
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HATs acetylate histones
  • Notch-HLH transcription pathway
  • B-WICH complex positively regulates rRNA expression
  • Physiological factors
  • Metalloprotease DUBs
  • RNA Polymerase I Transcription Initiation
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • Regulation of FOXO transcriptional activity by acetylation
  • Formation of WDR5-containing histone-modifying complexes
  • Formation of paraxial mesoderm
  • Coenzyme A
  • (3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE
  • N-(3-AMINOPROPYL)-2-NITROBENZENAMINE
KDR kinase insert domain receptor
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • Linifanib
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
  • Olinvacimab
KMT2A lysine methyltransferase 2A
  • PKMTs methylate histone lysines
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Transcriptional regulation of granulopoiesis
  • Formation of WDR5-containing histone-modifying complexes
  • Regulation of PD-L1(CD274) transcription
  • Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes
  • Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters
  • The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
KMT2D lysine methyltransferase 2D
  • Formation of the beta-catenin:TCF transactivating complex
  • PKMTs methylate histone lysines
  • Deactivation of the beta-catenin transactivating complex
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • Formation of WDR5-containing histone-modifying complexes
  • Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome
  • Kabuki syndrome
LATS2 large tumor suppressor kinase 2
  • Signaling by Hippo
LEF1 lymphoid enhancer binding factor 1
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • Deactivation of the beta-catenin transactivating complex
  • Ca2+ pathway
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates WNT signaling
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Etacrynic acid
LEO1 LEO1 component of Paf1/RNA polymerase II complex
  • Formation of RNA Pol II elongation complex
  • Formation of the beta-catenin:TCF transactivating complex
  • RNA Polymerase II Pre-transcription Events
  • RNA Polymerase II Transcription Elongation
  • E3 ubiquitin ligases ubiquitinate target proteins
MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1
MAGI2 membrane associated guanylate kinase, WW and PDZ domain containing 2
  • Nephrin family interactions
MAP3K2 mitogen-activated protein kinase kinase kinase 2
  • Bosutinib
  • Fostamatinib
MAPK8 mitogen-activated protein kinase 8
  • Activation of BIM and translocation to mitochondria
  • Activation of BMF and translocation to mitochondria
  • NRAGE signals death through JNK
  • NRAGE signals death through JNK
  • NRIF signals cell death from the nucleus
  • Oxidative Stress Induced Senescence
  • FCERI mediated MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Activation of the AP-1 family of transcription factors
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-38 signaling
  • WNT5:FZD7-mediated leishmania damping
  • Signaling by ALK fusions and activated point mutants
  • Tamoxifen
  • Minocycline
  • Pyrazolanthrone
  • 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE
  • 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
  • N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
  • 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE
  • 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide
  • Halicin

Page 6 out of 11 pages